associ
delayedphas
thrombocytopenia
occur
percent
enrol
patient
delayedphas
thrombocytopenia
prone
develop
elderli
patient
patient
low
lymphocyt
count
admiss
delayedphas
thrombocytopenia
significantli
associ
increas
length
hospit
stay
higher
icu
admiss
rate
delayedphas
nadir
platelet
count
demonstr
high
significantli
neg
linear
correl
b
cell
percentag
serum
level
also
present
bone
marrow
aspir
patholog
three
patient
delayedphas
thrombocytopenia
show
impair
matur
megakaryocyt
specul
delayedphas
platelet
destruct
might
mediat
antibodi
suggest
immunoregulatori
treatment
sever
patient
improv
outcom
besid
clinician
need
pay
attent
delayedphas
thrombocytopenia
especi
week
symptom
onset
decemb
outbreak
sever
viral
pneumonia
unknown
origin
initi
report
wuhan
china
novel
coronaviru
identifi
caus
agent
firstli
name
novel
coronaviru
diseas
eventu
term
coronaviru
diseas
viru
sever
acut
respiratori
syndrom
coronaviru
pandem
engulf
entir
world
estim
mortal
rate
common
symptom
includ
fever
cough
short
breath
sinc
lung
major
target
muscl
pain
sputum
product
diarrhea
sore
throat
loss
tast
andor
loss
smell
possibl
less
common
cardiac
neurolog
complic
also
found
extrapulmonari
manifest
impli
divers
target
organ
addit
lung
hematopoiet
system
also
affect
multicent
studi
hospit
center
demonstr
admiss
lymphocytopenia
present
patient
thrombocytopenia
leukopenia
increas
hospit
capac
prolong
isol
period
abl
studi
diseas
longitudin
apart
crosssect
admiss
particular
initi
observ
show
sudden
dramat
declin
platelet
count
sever
patient
without
evid
coagul
abnorm
happen
three
week
symptom
onset
relat
earlyphas
thrombocytopenia
preval
latephas
delayedphas
thrombocytopenia
obscur
current
studi
report
incid
characterist
outcom
patient
delayedphas
thrombocytopenia
also
present
bone
marrow
aspir
patholog
three
patient
delayedphas
thrombocytopenia
retrospect
descript
longitudin
studi
conduct
januari
march
analysi
began
march
patient
recruit
union
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
two
inclus
criteria
studi
patient
confirm
realtim
revers
transcript
pcr
realtim
rtpcr
diagnos
accord
interim
guidanc
patient
underw
chest
computer
tomographi
ct
complet
panel
routin
laboratori
test
includ
compet
blood
count
blood
biochemistri
blood
coagul
function
test
key
inflammatori
cytokin
lymphocyt
subset
analysi
exclus
criteria
monitor
period
less
day
symptom
onset
autoimmun
hematolog
diseas
histori
previou
human
immunodefici
viru
hiv
hepat
b
hepat
c
infect
dialysi
patient
patient
screen
inclus
exclus
criteria
describ
demograph
data
clinic
characterist
laboratori
data
chest
ct
scan
find
treatment
program
outcom
obtain
patient
medic
record
clinic
outcom
follow
march
miss
uncertain
record
collect
clarifi
direct
commun
involv
healthcar
provid
famili
data
review
train
team
physician
data
separ
extract
two
author
peng
yang
hao
zhou
collect
data
age
gender
respiratori
rate
smoke
comorbid
hepat
b
hepat
c
hiv
hepatosplenomegali
hematolog
system
diseas
rheumat
immun
system
diseas
cardio
cerebrovascular
diseas
endocrin
system
diseas
respiratori
system
diseas
digest
system
diseas
nervou
system
diseas
malign
tumor
symptom
onset
hospit
admiss
fever
cough
dyspnea
pharyngalgia
diarrhea
anorexia
abdomin
pain
palpit
hypodynamia
paresthesia
myalgia
dizzi
laboratori
valu
admiss
blood
routin
blood
coagul
function
blood
biochemistri
creactiv
protein
inflammatori
cytokin
lymphocyt
subset
treatment
antivir
agent
antibacteri
agent
antifung
agent
corticosteroid
inhal
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
immunoglobulin
oxygen
therapi
well
live
statu
furthermor
collect
continu
monitor
laboratori
data
includ
blood
routin
blood
coagul
function
inflammatori
cytokin
lymphocyt
subset
analysi
patient
igg
antibodi
result
record
avail
date
diseas
onset
defin
day
symptom
notic
sever
defin
accord
diagnost
criteria
diagnosi
treatment
plan
trial
seventh
edit
issu
nation
health
commiss
peopl
republ
china
throat
swab
sampl
collect
place
collect
tube
contain
preserv
solut
viru
confirm
realtim
rtpcr
assay
nucleic
acid
detect
kit
shanghai
biogerm
medic
technolog
shanghai
china
igg
antibodi
detect
igg
antibodi
detect
kit
yhlo
biotechnolog
shenzhen
china
extract
demograph
data
clinic
characterist
includ
respiratori
extrarespiratori
symptom
admiss
comorbid
laboratori
data
treatment
program
clinic
outcom
remain
hospit
isol
ward
icu
discharg
die
outcom
categori
use
previou
studi
descript
data
present
mean
standard
deviat
sd
normal
distribut
continu
variabl
median
interquartil
rang
iqr
nonnorm
distribut
data
categor
variabl
present
percentag
two
independ
sampl
test
ttest
analysi
varianc
kruskalw
rank
sum
test
appli
comparison
multipl
group
proport
categor
variabl
compar
use
test
although
fisher
exact
test
use
data
limit
pearson
correl
coeffici
spearman
rank
correl
coeffici
use
liner
correl
analysi
statist
analysi
perform
use
spss
v
ibm
corp
armonk
ny
usa
twotail
p
valu
consid
statist
signific
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
result
analyz
popul
covid
intraven
immunoglobulin
addit
patient
transfer
icu
still
remain
hospit
isol
ward
time
studi
complet
discharg
die
among
discharg
patient
averag
hospit
isol
ward
stay
day
sd
base
presum
viremia
phase
infect
preliminari
clinic
observ
propos
set
day
rough
reason
feasibl
cutoff
valu
therefor
delayedphas
thrombocytopenia
defin
thrombocytopenia
begin
worsen
day
post
symptom
appear
found
patient
develop
delayedphas
thrombocytopenia
median
time
delayedphas
thrombocytopenia
nadir
appear
day
ill
onset
median
durat
time
delayedphas
thrombocytopenia
sd
also
found
mean
platelet
count
nadir
l
sd
delayedphas
thrombocytopenia
preval
elderli
person
patient
clinic
outcom
hospit
isol
ward
icu
discharg
die
patient
delayedphas
thrombocytopenia
patient
remain
hospit
isol
ward
patient
discharg
patient
icu
patient
die
repres
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
platelet
count
curv
patient
shown
figur
delayedphas
thrombocytopenia
case
demonstr
lower
lymphocyt
count
p
higher
level
lactat
dehydrogenas
ul
p
compar
group
without
delayedphas
thrombocytopenia
tabl
meanwhil
level
lymphocyt
subset
includ
b
cell
show
signific
alter
counterpart
bunch
key
inflammatori
cytokin
also
chang
delayedphas
thrombocytopenia
patient
includ
notwithstand
platelet
lymphocyt
ration
plr
show
discrep
patient
without
delayedphas
thrombocytopenia
furthermor
signific
differ
level
white
blood
cell
count
platelet
count
coagul
indic
patient
without
delayedphas
thrombocytopenia
admiss
conduct
timecorrel
data
analysi
laboratori
chang
underlin
cytokin
lymphocyt
immun
tabl
review
inflammatori
cytokin
result
around
time
delayedphas
thrombocytopenia
occur
result
show
around
platelet
count
nadir
time
point
median
level
pgml
pgml
pgml
significantli
higher
upper
limit
normal
valu
lymphocyt
subset
monitor
delayedphas
plate
count
nadir
time
show
percentag
cell
b
cell
averag
normal
valu
delayedphas
nadir
platelet
count
demonstr
high
significantli
neg
linear
correl
b
cell
percentag
p
serum
level
p
figur
specif
studi
three
patient
underw
bone
marrow
aspir
union
hospit
three
patient
develop
rapid
dramat
declin
platelet
count
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
delay
phase
without
evid
coagul
abnorm
patholog
result
three
patient
share
common
featur
bone
marrow
show
obviou
abnorm
myeloid
erythroid
cell
number
atyp
reactiv
lymphocyt
increas
matur
megakaryocyt
impair
matur
plateletproduc
megakaryocyt
rare
megakaryocyt
immatur
granular
megakaryocyt
two
patient
bone
marrow
smear
imag
present
figur
figur
matur
plateletproduc
megakaryocyt
attach
three
platelet
one
larg
two
small
might
suggest
bodi
compens
make
abnorm
larg
platelet
present
studi
conduct
review
medic
record
patient
januari
march
heavili
affect
hospit
initi
outbreak
china
found
associ
delayedphas
thrombocytopenia
occur
percent
enrol
patient
delayedphas
thrombocytopenia
prone
develop
elderli
patient
patient
low
lymphocyt
count
admiss
delayedphas
thrombocytopenia
significantli
associ
increas
length
hospit
stay
higher
icu
admiss
rate
began
studi
base
clinic
observ
occasion
sever
patient
develop
rapid
platelet
count
decreas
week
treatment
without
evid
coagul
abnorm
rare
case
even
suffer
sever
delayedphas
thrombocytopenia
platelet
l
consid
natur
cours
viral
infect
treatment
outcom
patient
week
symptom
onset
patient
recoveri
stage
paradox
delayedphas
thrombocytopenia
prompt
us
investig
preval
characterist
expand
hospit
capac
prolong
isol
period
patient
admit
time
laboratori
result
well
followedup
enabl
us
conduct
longitudin
studi
dynam
chang
platelet
count
studi
show
delayedphas
thrombocytopenia
preval
enrol
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
previou
report
contagi
coronaviru
case
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
suggest
thrombocytopenia
common
sar
mer
patient
howev
viral
infect
associ
delayedphas
thrombocytopenia
mere
report
rare
case
report
without
enough
patient
statist
analysi
clarifi
pathogenesi
delayedphas
thrombocytopenia
screen
laboratori
result
underlin
key
cytokin
lymphocyt
immun
result
suggest
strong
inflammatori
cytokin
neg
correl
delayedphas
platelet
count
declin
indic
might
activ
player
delayedphas
platelet
declin
notabl
timecorrel
lymphocyt
subset
analysi
show
b
cell
percentag
neg
associ
delayedphas
thrombocytopenia
sinc
antibodi
product
b
cell
crucial
viru
protect
result
highlight
import
role
antibodi
play
delayedphas
platelet
decreas
also
found
delayedphas
thrombocytopenia
last
less
day
impli
delayedphas
thrombocytopenia
transient
furthermor
sought
obtain
evid
bone
marrow
bone
marrow
aspir
analysi
help
recogn
possibl
pathogenesi
hematopoiet
tissu
bone
marrow
aspir
patholog
show
common
featur
imped
megakaryocyt
matur
matur
plateletproduc
megakaryocyt
rare
less
bone
marrow
smear
bone
marrow
featur
similar
immun
thrombocytopenia
impair
megakaryocyt
matur
insuffici
platelet
product
particip
pathogenesi
immun
thrombocytopenia
timepoint
platelet
count
nadir
three
patient
nucleic
acid
neg
twice
suggest
viru
delet
suppress
igg
antibodi
posit
suggest
protect
antibodi
produc
base
antibodi
product
curv
infect
specul
delayedphas
platelet
destruct
mediat
antibodi
viru
associ
immun
thrombocytopenia
may
includ
sever
mechan
firstli
virusinduc
chang
host
immun
system
polyclon
b
cell
activ
releas
cytokin
secondli
product
autoantibodi
platelet
glycoprotein
induc
modif
platelet
surfac
protein
viru
infect
thirdli
crossreact
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
viru
proteindirect
antibodi
platelet
glycoprotein
fourthli
viru
infect
megakaryocyt
shed
platelet
present
viral
antigen
antivir
antibodi
attack
platelet
anim
model
rauscher
viru
infect
show
viral
antigen
express
platelet
correl
develop
delayedphas
thrombocytopenia
ground
treatment
use
immunoregulatori
agent
includ
intraven
immunoglobulin
ivig
dexamethason
reason
necessari
ivig
administ
three
patient
thereaft
prove
effect
day
zika
virusinfect
patient
suffer
sever
thrombocytopenia
day
ill
onset
treat
presum
immunemedi
thrombocytopenia
ivig
platelet
recov
day
studi
sever
limit
first
analysi
base
retrospect
studi
rel
small
sampl
could
caus
bias
limit
reliabl
result
second
laboratori
data
monitor
strictli
fix
time
interv
due
rapidli
evolv
epidem
might
lead
omiss
data
chang
time
point
third
hospitalbas
studi
doubt
miss
patient
mild
case
treat
home
studi
cohort
may
repres
sever
end
fourth
multivari
regress
analysi
recommend
recogn
risk
factor
individu
odd
ratio
studi
integr
clinic
charact
need
draw
complet
conclus
fifth
sever
patient
still
hospit
inform
regard
clinic
outcom
unavail
time
write
relationship
patient
prognosi
delayedphas
thrombocytopenia
remain
investig
summari
demonstr
preval
delayedphas
thrombocytopenia
patient
rare
case
patient
even
suffer
lifethr
thrombocytopenia
compar
without
delayedphas
thrombocytopenia
patient
delayedphas
thrombocytopenia
longer
hospit
stay
time
wors
clinic
outcom
present
descript
data
suggest
associ
delayedphas
thrombocytopenia
antivir
immun
highlight
ration
immunoregulatori
treatment
result
encourag
research
evalu
preval
incid
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
predictor
outcom
delayedphas
thrombocytopenia
ongo
pandem
meanwhil
doctor
need
pay
attent
delayedphas
thrombocytopenia
especi
week
symptom
onset
median
time
delayedphas
thrombocytopenia
occurr
knowledg
may
help
doctor
time
appli
immunoregulatori
treatment
thu
improv
outcom
igg
product
curv
b
variat
tendenc
ten
repres
patient
without
delayedphas
thrombocytopenia
correl
b
lymphocyt
percentag
serum
interleukin
platelet
count
delayedphas
platelet
nadir
time
point
wright
stain
bone
marrow
aspir
smear
two
patient
red
arrow
granular
megakaryocyt
b
red
arrow
granular
megakaryocyt
c
red
arrow
atyp
reactiv
lymphocyt
x
red
arrow
granular
megakaryocyt
e
red
arrow
plateletproduc
megakaryocyt
yellow
arrow
one
larg
two
small
platelet
f
red
arrow
matur
lymphocyt
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
